Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

Illumina, Inc. will acquire SomaLogic for $350 million plus performance-based milestones. The acquisition advances Illumina's multiomics strategy, combining SomaLogic's proteomics technology with ...

Leveraging Illumina's advanced spatial technology, which provides an expansive 50 mm by 15 mm imaging area for enhanced flexibility, sensitivity, resolution, and unbiased whole-transcriptome ...

For reference, after the Human Genome Project took 13 years and $2.7 billion to complete in 2003, Illumina’s technology helped reduce the cost of whole genome sequencing faster than Moore’s ...

Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), ...

Illumina stock slid on Tuesday after China banned imports of the biotech’s gene sequencing machines as part of a broader retaliatory response to U.S. tariffs. Shares of Illumina slipped 3.6% to ...

Illumina inked a deal with Standard BioTools to acquire SomaLogic for $350 million in cash. The maker of gene-sequencing equipment and services said Monday that the deal includes an additional payout ...

Illumina to acquire SomaLogic, a leader in data-driven proteomics technology, for $350 million: San Diego Tuesday, June 24, 2025, 12:00 Hrs [IST] Illumina, Inc., a global leader i ...

Illumina expects the addition of a high-margin revenue stream, although the deal is expected to close in 2026.